These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 27793044)

  • 1. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
    Li J; Zhou L; Chen X; Ba Y
    Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
    Zhou M; Yu P; Qu X; Liu Y; Zhang J
    PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment.
    Ding SS; Li L; Yu CX
    J BUON; 2014; 19(4):965-72. PubMed ID: 25536603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang S; Mao XD; Wang HT; Cai F; Xu J
    BMJ Open; 2016 Jun; 6(6):e011714. PubMed ID: 27363819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.
    Marchetti C; De Felice F; Palaia I; Musella A; Di Donato V; Gasparri ML; Musio D; Muzii L; Tombolini V; Panici PB
    Oncotarget; 2016 Mar; 7(11):13221-7. PubMed ID: 26657509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
    Hu W; Xu WS; Liao XF; He HJ
    Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer.
    Wang TS; Lei W; Cui W; Wen P; Guo HF; Ding SG; Yang YP; Xu YQ; Lv SW; Zhu YL
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e95-8. PubMed ID: 25818743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
    Liang RF; Zheng LL
    Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
    Ye Q; Chen HL
    Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.
    Li X; Zhu S; Hong C; Cai H
    Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
    Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis.
    Yang Y; Wang L; Li X; Zhang S; Yu J; Nie X; Liu W; Wu X; Zhang P; Li Y; Li A; Ai B
    Thorac Cancer; 2022 Jan; 13(1):31-37. PubMed ID: 34859599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
    Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
    In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
    Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
    Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.